LINC02446: A Potential Drug Target and Biomarker (G101060038)

Target Name: LINC02446

NCBI ID: G101060038

LINC02446

Other Name(s): long intergenic non-protein coding RNA 2446 | Long intergenic non-protein coding RNA 2446, transcript variant 1

LINC02446: A Potential Drug Target and Biomarker

LINC02446 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell鈥檚 immune response and has been involved in various cellular processes, including cell division, apoptosis, and inflammation. LINC02446 is also known as IDH1, and its dysfunction has been linked to various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

The IDH1 gene

IDH1 is a gene that encodes a non-coding RNA molecule with unique features, including a stem-like structure and the presence of a hypervariable region (HVR). The HVR is a region of variable length that is involved in the regulation of IDH1 protein, and has been implicated in various cellular processes, including DNA replication, cell growth, and stress response.

IDH1 mutations

Mutations in the IDH1 gene have been linked to various diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, IDH1 mutations have been implicated in the development of neurofibrillary tangles in Alzheimer鈥檚 disease, a hallmark of the disease that is characterized by the accumulation of neurofibrillary tangles in the brain. In addition, IDH1 mutations have also been linked to the development of various cancers, including breast, ovarian, and colorectal cancers.

LINC02446 as a drug target

LINC02446 has been identified as a potential drug target due to its involvement in the regulation of the immune response and its unique structure. LINC02446 is a key regulator of T cell development and has been shown to play a role in the regulation of cell death, apoptosis, and inflammation. In addition, LINC02446 has also been shown to be involved in the regulation of cancer cell survival and has been linked to the development of various cancers.

LINC02446 as a biomarker

LINC02446 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, LINC02446 has been shown to be involved in the regulation of cancer cell growth and has been linked to the development of various cancers, including breast, ovarian, and colorectal cancers. In addition, LINC02446 has also been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer鈥檚 disease, and has been linked to the accumulation of neurofibrillary tangles in the brain.

Conclusion

In conclusion, LINC02446 is a non-coding RNA molecule that has unique features and has been involved in various cellular processes, including cell division, apoptosis, and inflammation. Its dysfunction has been linked to various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Therefore, LINC02446 is a potential drug target and biomarker, and further research is needed to understand its role in various biological processes and its potential as a therapeutic approach.

Protein Name: Long Intergenic Non-protein Coding RNA 2446

The "LINC02446 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02446 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets